 Fennec Pharmaceuticals Inc. Nasdaq: FENC; TSX: FRX, a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration FDA has accepted for filing and granted Priority Review for the companys New Drug Application NDA for PEDMARKTM a unique formulation of sodium thiosulfate. PEDMARK is an investigational drug for the prevention of ototoxicity induced by cisplatin chemotherapy in patients one month to 18 years of age with localized, non-metastatic, solid tumors. 